Last reviewed · How we verify
Gemcitabine, local delivery
At a glance
| Generic name | Gemcitabine, local delivery |
|---|---|
| Also known as | Gemzar |
| Sponsor | RenovoRx |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma (PHASE2)
- PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) (PHASE1, PHASE2)
- Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)
- A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer. (PHASE3)
- A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer (NA)
- Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer. (PHASE1, PHASE2)
- Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) (NA)
- PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine, local delivery CI brief — competitive landscape report
- Gemcitabine, local delivery updates RSS · CI watch RSS
- RenovoRx portfolio CI